Drug Search Results
More Filters [+]

Somatostatin

Alternative Names: somatostatin
Latest Update: 2024-04-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: SSTR Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Italy | Jordan | Korea | Luxembourg | Malta | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Switzerland | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: BCN Peptides
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Somatostatin

Countries in Clinic: Hungary, Lithuania, Poland, Russia, Serbia, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acromegaly|Carcinoid Tumor

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02795858

P2

Active, not recruiting

Carcinoid Tumor

2022-12-31

ISIS 766720-CS3

P2

Completed

Acromegaly

2022-03-31

24%

ISIS 766720-CS3

P2

Completed

Acromegaly

2022-03-31

24%

Recent News Events